

Edgar Filing: Johann Peter - Form 3

	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	
Series A Preferred Stock	Â (3)	Â (3)	Common Stock	401,927	\$ (3)	I	See Footnotes (1) (4)
Series A Preferred Stock	Â (3)	Â (3)	Common Stock	555,956	\$ (3)	I	See Footnotes (2) (4)
Series B Preferred Stock	Â (3)	Â (3)	Common Stock	44,364	\$ (3)	I	See Footnotes (1) (4)
Series B Preferred Stock	Â (3)	Â (3)	Common Stock	61,366	\$ (3)	I	See Footnotes (2) (4)
Convertible Promissory Notes	Â (5)	Â (5)	Common Stock	805,656.5 (5)	\$ (5)	I	See Footnotes (1) (4)
Convertible Promissory Notes	Â (5)	Â (5)	Common Stock	1,114,382.5 (5)	\$ (5)	I	See Footnotes (2) (4)

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Johann Peter C/O HORIZON PHARMA, INC. 1033 SKOKIE BLVD., SUITE 355 NORTHBROOK, IL 60062	Â X	Â X	Â	Â

Signatures

/s/ Robert J. De vaere,
attorney-in-fact

07/28/2011

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
 - ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Held of record by NGN Biomed Opportunity I GmbH & Co. Beteiligungs KG ("NGN Biomed GmbH").
 - (2) Held of record by NGN Biomed Opportunity I, L.P. ("NGN Biomed").
The shares of Series A Preferred Stock and Series B Preferred Stock have no expiration date and are convertible at any time at the election of the holder. Every 2.374 shares of preferred stock will automatically convert into one share of common stock upon the closing of the Issuer's initial public offering.
 - (3) The reporting person is a Managing General Partner of NGN Capital LLC, which is the general partner of the general partner of NGN BioMed and is the managing limited partner of NGN BioMed GMBH. The Reporting Person disclaims beneficial ownership with respect to these securities, except to the extent of his pecuniary interest therein.
 - (5) Principal and accrued interest will convert upon the Issuer's initial public offering into shares of Common Stock at a conversion price equal to the lesser of (i) the public offering price of the Common Stock sold in the Issuer's initial public offering, or (ii) \$18.92. Amounts

Edgar Filing: Johann Peter - Form 3

shown are reported in US dollars and include interest accrued through the date hereof; additional interest will accrue prior to conversion.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.